Remove Access Remove Cannabinoids Remove Clinical Trials Remove Pharmaceutical
article thumbnail

Clinical Trial: Cannabinoid Administration Via a Metered-Dose Inhaler Is Safe and Effective for Chronic Pain Patients

NORML

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Additional information regarding cannabinoids and pain appears online h ere.

article thumbnail

New U.S. Research Efforts Could Catalyze Medical Cannabis’ Adoption in the Pharmaceutical Industry

Veriheal

The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Science Behind Medical Marijuana: Exploring Cannabinoids and Their Therapeutic Effects

MMJ Recs

This article delves into the science behind medical marijuana, focusing on cannabinoids, the active compounds found in the cannabis plant, and their remarkable therapeutic effects. We’ll explore the diverse range of cannabinoids and their health benefits, providing insights into how these compounds are revolutionizing healthcare.

article thumbnail

Oxford Cannabinoid Technologies Holdings plc: Post IPO Review & Notice of Pre-Close Trading Update

Cannabis Law Report

On 1 June 2021, the Group announced an agreement with Voisin Consulting SARL (“VC”), a life sciences consultancy comprising over 200 professionals in the UK, US and India, with expertise in medical devices, cannabinoids, neurological disorders and addictions.

article thumbnail

Exclusive Worldwide License Agreement with Canopy Growth Corporation for Key Pharmaceutical Assets

Cannabis Law Report

Oxford Cannabinoid Technologies Holdings plc. . Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. Accelerated timelines to clinical trials and expansion of drug development pipeline. Exclusive licensing agreement with leading global cannabis company (“Canopy Growth”).

article thumbnail

Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director

Cannabis Law Report

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. I am so very proud of all Anebulo has achieved over the past 18 months, including building out a highly effective team, securing new intellectual property protection, preparing and starting a proof-of-concept clinical trial, advancing regulatory discussions with the U.S.

article thumbnail

MyMD Pharmaceuticals to Participate in Two Investor Conferences During December 2021

Cannabis Law Report

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. About Supera-CBD.